Abeona Therapeutics Announces first patient treatment with Zevaskyn gene therapy for recessive dystrophic epidermolysis bullosa

Abeona Therapeutics Inc. announced the first patient treatment with FDA-approved Zevaskyn (prademagene zamikeracel), a first-of-its-kind, autologous gene therapy for treating wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). Zevaskyn was administered at Lucile Packard Children’s Hospital Stanford in Palo Alto, CA.

“Treating our first patient is a proud moment for Abeona and a testament to the tireless resolve of our team,” said Vish Seshadri, Chief Executive Officer of Abeona. “We are humbled to bring ZEVASKYN to the RDEB community and grateful to our growing network of Qualified Treatment Centers. Momentum is building, with additional patients already scheduled for treatment in the new year.”

Dr. Joyce Teng, professor of dermatology at Stanford Medicine and chief of pediatric dermatology at Stanford Medicine Children’s Health, said, “We continually pursue new therapies to support patients enduring the lifelong pain and extensive wound care that RDEB demands, and work to provide care and hope to patients and families.”